ASCO 2023 | Using tumor-informed MRD to find biomarkers in cancer

Junqiang Yin, MD, PhD, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, discusses the role of tumor-informed minimal residual disease (MRD) as a tool to find biomarkers. Tumor-informed MRD can detect tumor tissue, which is unique for patient cancer cells. This differs from tumor agnostic MRD techniques, as these are universal panels that may not be suitable for sarcoma patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.